1
|
Reincke SM, Yuan M, Kornau HC, Corman VM, van Hoof S, Sánchez-Sendin E, Ramberger M, Yu W, Hua Y, Tien H, Schmidt ML, Schwarz T, Jeworowski LM, Brandl SE, Rasmussen HF, Homeyer MA, Stöffler L, Barner M, Kunkel D, Huo S, Horler J, von Wardenburg N, Kroidl I, Eser TM, Wieser A, Geldmacher C, Hoelscher M, Gänzer H, Weiss G, Schmitz D, Drosten C, Prüss H, Wilson IA, Kreye J. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science 2022; 375:782-787. [PMID: 35076281 PMCID: PMC8939768 DOI: 10.1126/science.abm5835] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Accepted: 01/18/2022] [Indexed: 12/16/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type-elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Neutralizing/chemistry
- Antibodies, Neutralizing/genetics
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/genetics
- Antibodies, Viral/immunology
- Antibodies, Viral/metabolism
- Antigenic Drift and Shift
- COVID-19/immunology
- COVID-19/virology
- Cross Reactions
- Female
- Humans
- Male
- Middle Aged
- Neutralization Tests
- Protein Binding
- Protein Domains
- Protein Interaction Domains and Motifs
- SARS-CoV-2/chemistry
- SARS-CoV-2/genetics
- SARS-CoV-2/immunology
- Spike Glycoprotein, Coronavirus/chemistry
- Spike Glycoprotein, Coronavirus/genetics
- Spike Glycoprotein, Coronavirus/immunology
- Spike Glycoprotein, Coronavirus/metabolism
Collapse
Affiliation(s)
- S. Momsen Reincke
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Meng Yuan
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Hans-Christian Kornau
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Neuroscience Research Center (NWFZ), Cluster NeuroCure, Berlin, Germany
| | - Victor M. Corman
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany
- Labor Berlin–Charité Vivantes GmbH, Berlin
| | - Scott van Hoof
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Elisa Sánchez-Sendin
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Melanie Ramberger
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Wenli Yu
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Yuanzi Hua
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Henry Tien
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Marie Luisa Schmidt
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany
| | - Tatjana Schwarz
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany
| | - Lara Maria Jeworowski
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany
| | - Sarah E. Brandl
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Helle Foverskov Rasmussen
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Marie A. Homeyer
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Laura Stöffler
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Martin Barner
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Désirée Kunkel
- Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Flow and Mass Cytometry Core Facility, Berlin, Germany
| | - Shufan Huo
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
| | - Johannes Horler
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Niels von Wardenburg
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
- German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Tabea M. Eser
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
- German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
- German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Christof Geldmacher
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
- German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
- German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Hannes Gänzer
- Department of Internal Medicine, BKH Schwaz, Schwaz, Austria
| | - Günter Weiss
- Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria
| | - Dietmar Schmitz
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Neuroscience Research Center (NWFZ), Cluster NeuroCure, Berlin, Germany
| | - Christian Drosten
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany
| | - Harald Prüss
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
| | - Ian A. Wilson
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
- The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Jakob Kreye
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Pediatric Neurology, Berlin, Germany
| |
Collapse
|
2
|
Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, Schwarz T, Mangold M, Unger C, Dörfler F, Kadler S, Rosowski J, Gürcan K, Uyar-Aydin Z, Frentsch M, Kurth F, Schnatbaum K, Eckey M, Hippenstiel S, Hocke A, Müller MA, Sawitzki B, Miltenyi S, Paul F, Mall MA, Wenschuh H, Voigt S, Drosten C, Lauster R, Lachman N, Sander LE, Corman VM, Röhmel J, Meyer-Arndt L, Thiel A, Giesecke-Thiel C. Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science 2021; 374:eabh1823. [PMID: 34465633 PMCID: PMC10026850 DOI: 10.1126/science.abh1823] [Citation(s) in RCA: 175] [Impact Index Per Article: 58.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The functional relevance of preexisting cross-immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)–reactive and SARS-CoV-2–cross-reactive CD4+ T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that preexisting spike- and S816-830–reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti–SARS-CoV-2-S1-IgG antibodies. Spike–cross-reactive T cells were also activated after primary BNT162b2 COVID-19 messenger RNA vaccination and displayed kinetics similar to those of secondary immune responses. Our results highlight the functional contribution of preexisting spike–cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 disease courses.
Collapse
Affiliation(s)
- Lucie Loyal
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Julian Braun
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Larissa Henze
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Beate Kruse
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Manuela Dingeldey
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Ulf Reimer
- JPT Peptide Technologies GmbH, Berlin, Germany
| | - Florian Kern
- JPT Peptide Technologies GmbH, Berlin, Germany
- Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK
| | - Tatjana Schwarz
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Maike Mangold
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Clara Unger
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Friederike Dörfler
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Shirin Kadler
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Jennifer Rosowski
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Kübrah Gürcan
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Zehra Uyar-Aydin
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Marco Frentsch
- Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Florian Kurth
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Maren Eckey
- JPT Peptide Technologies GmbH, Berlin, Germany
| | - Stefan Hippenstiel
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Hocke
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Marcel A. Müller
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany
| | - Birgit Sawitzki
- Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | | | - Friedemann Paul
- Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Marcus A. Mall
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Center for Lung Research, Associated Partner, Berlin, Germany
| | | | - Sebastian Voigt
- Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany
- Institute for Virology, Universitätsklinikum Essen, Essen, Germany
| | - Christian Drosten
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany
| | - Roland Lauster
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Nils Lachman
- Institute for Transfusion Medicine, Tissue Typing Laboratory, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Leif-Erik Sander
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Victor M. Corman
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany
| | - Jobst Röhmel
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Lil Meyer-Arndt
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology and Experimental Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Thiel
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Corresponding author. (A.T.); (C.G.-T.)
| | - Claudia Giesecke-Thiel
- Max Planck Institute for Molecular Genetics, Berlin, Germany
- Corresponding author. (A.T.); (C.G.-T.)
| |
Collapse
|
3
|
Widera M, Mühlemann B, Corman VM, Toptan T, Beheim-Schwarzbach J, Kohmer N, Schneider J, Berger A, Veith T, Pallas C, Bleicker T, Goetsch U, Tesch J, Gottschalk R, Jones TC, Ciesek S, Drosten C. Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. Microorganisms 2021; 9:748. [PMID: 33918332 PMCID: PMC8065810 DOI: 10.3390/microorganisms9040748] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 03/30/2021] [Accepted: 03/30/2021] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND International travel is a major driver of the introduction and spread of SARS-CoV-2. AIM To investigate SARS-CoV-2 genetic diversity in the region of a major transport hub in Germany, we characterized the viral sequence diversity of the SARS-CoV-2 variants circulating in Frankfurt am Main, the city with the largest airport in Germany, from the end of October to the end of December 2020. METHODS In total, we recovered 136 SARS-CoV-2 genomes from nasopharyngeal swab samples. We isolated 104 isolates that were grown in cell culture and RNA from the recovered viruses and subjected them to full-genome sequence analysis. In addition, 32 nasopharyngeal swab samples were directly sequenced. RESULTS AND CONCLUSION We found 28 different lineages of SARS-CoV-2 circulating during the study period, including the variant of concern B.1.1.7 (Δ69/70, N501Y). Six of the lineages had not previously been observed in Germany. We detected the spike protein (S) deletion Δ69/Δ70 in 15% of all sequences, a four base pair (bp) deletion (in 2.9% of sequences) and a single bp deletion (in 0.7% of sequences) in ORF3a, leading to ORF3a truncations. In four sequences (2.9%), an amino acid deletion at position 210 in S was identified. In a single sample (0.7%), both a 9 bp deletion in ORF1ab and a 7 bp deletion in ORF7a were identified. One sequence in lineage B.1.1.70 had an N501Y substitution while lacking the Δ69/70 in S. The high diversity of sequences observed over two months in Frankfurt am Main highlights the persisting need for continuous SARS-CoV-2 surveillance using full-genome sequencing, particularly in cities with international airport connections.
Collapse
Affiliation(s)
- Marek Widera
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany; (T.T.); (N.K.); (A.B.); (C.P.); (S.C.)
| | - Barbara Mühlemann
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Victor M. Corman
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Tuna Toptan
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany; (T.T.); (N.K.); (A.B.); (C.P.); (S.C.)
| | - Jörn Beheim-Schwarzbach
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Niko Kohmer
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany; (T.T.); (N.K.); (A.B.); (C.P.); (S.C.)
| | - Julia Schneider
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Annemarie Berger
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany; (T.T.); (N.K.); (A.B.); (C.P.); (S.C.)
| | - Talitha Veith
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Christiane Pallas
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany; (T.T.); (N.K.); (A.B.); (C.P.); (S.C.)
| | - Tobias Bleicker
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Udo Goetsch
- Public Health Department of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany; (U.G.); (R.G.)
| | - Julia Tesch
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
| | - Rene Gottschalk
- Public Health Department of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany; (U.G.); (R.G.)
| | - Terry C. Jones
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
- Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing St., Cambridge CB2 3EJ, UK
| | - Sandra Ciesek
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany; (T.T.); (N.K.); (A.B.); (C.P.); (S.C.)
- German Center for Infection Research, DZIF, 60596 Braunschweig, Germany
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, 60596 Frankfurt am Main, Germany
| | - Christian Drosten
- German Centre for Infection Research (DZIF), Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt—Universität zu Berlin, 10117 Berlin, Germany; (B.M.); (V.M.C.); (J.B.-S.); (J.S.); (T.V.); (T.B.); (J.T.); (T.C.J.); (C.D.)
- German Center for Infection Research, DZIF, 60596 Braunschweig, Germany
| |
Collapse
|
4
|
Abstract
Combining its two traditions of integrated psychosomatics in internal medicine and focusing on psychotherapeutic/psychiatric methods in many clinical fields, German psychosomatic medicine has developed well over the last decades. It benefits from its institutional independence and the progressive changes in health care. Clinically, disorder-oriented psychotherapy is a core method integrated with other modes of therapy. As a conceptual base for empirical research, non-reductionist accounts of the interactions of (sick) persons with their environment are most important. Germany has developed a model of Psychosomatic Medicine that has conceptualized and integrated psychotherapeutic methods into clinical practice and realized one way to practice bio-psycho-social medicine in the health care system of the country.
Collapse
Affiliation(s)
- Hans-Christian Deter
- Medical Clinic, Psychosomatics, Charité, Hindenburgdamm 30, 12200 Berlin, Germany
| | - Johannes Kruse
- Clinic for Psychosomatic Medicine and Psychotherapy, German Association of Psychosomatic Medicine and Psychotherapy (DGPM), University Gießen und Marburg GmbH, Giessen, Germany
| | - Stephan Zipfel
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tuebingen, German College of Psychosomatic Medicine (DKPM), Tuebingen, Germany
| |
Collapse
|
5
|
Imamura F, Sharp SJ, Koulman A, Schulze MB, Kröger J, Griffin JL, Huerta JM, Guevara M, Sluijs I, Agudo A, Ardanaz E, Balkau B, Boeing H, Chajes V, Dahm CC, Dow C, Fagherazzi G, Feskens EJM, Franks PW, Gavrila D, Gunter M, Kaaks R, Key TJ, Khaw KT, Kühn T, Melander O, Molina-Portillo E, Nilsson PM, Olsen A, Overvad K, Palli D, Panico S, Rolandsson O, Sieri S, Sacerdote C, Slimani N, Spijkerman AMW, Tjønneland A, Tumino R, van der Schouw YT, Langenberg C, Riboli E, Forouhi NG, Wareham NJ. A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: The EPIC-InterAct case-cohort study. PLoS Med 2017; 14:e1002409. [PMID: 29020051 PMCID: PMC5636062 DOI: 10.1371/journal.pmed.1002409] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Accepted: 09/14/2017] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Combinations of multiple fatty acids may influence cardiometabolic risk more than single fatty acids. The association of a combination of fatty acids with incident type 2 diabetes (T2D) has not been evaluated. METHODS AND FINDINGS We measured plasma phospholipid fatty acids by gas chromatography in 27,296 adults, including 12,132 incident cases of T2D, over the follow-up period between baseline (1991-1998) and 31 December 2007 in 8 European countries in EPIC-InterAct, a nested case-cohort study. The first principal component derived by principal component analysis of 27 individual fatty acids (mole percentage) was the main exposure (subsequently called the fatty acid pattern score [FA-pattern score]). The FA-pattern score was partly characterised by high concentrations of linoleic acid, stearic acid, odd-chain fatty acids, and very-long-chain saturated fatty acids and low concentrations of γ-linolenic acid, palmitic acid, and long-chain monounsaturated fatty acids, and it explained 16.1% of the overall variability of the 27 fatty acids. Based on country-specific Prentice-weighted Cox regression and random-effects meta-analysis, the FA-pattern score was associated with lower incident T2D. Comparing the top to the bottom fifth of the score, the hazard ratio of incident T2D was 0.23 (95% CI 0.19-0.29) adjusted for potential confounders and 0.37 (95% CI 0.27-0.50) further adjusted for metabolic risk factors. The association changed little after adjustment for individual fatty acids or fatty acid subclasses. In cross-sectional analyses relating the FA-pattern score to metabolic, genetic, and dietary factors, the FA-pattern score was inversely associated with adiposity, triglycerides, liver enzymes, C-reactive protein, a genetic score representing insulin resistance, and dietary intakes of soft drinks and alcohol and was positively associated with high-density-lipoprotein cholesterol and intakes of polyunsaturated fat, dietary fibre, and coffee (p < 0.05 each). Limitations include potential measurement error in the fatty acids and other model covariates and possible residual confounding. CONCLUSIONS A combination of individual fatty acids, characterised by high concentrations of linoleic acid, odd-chain fatty acids, and very long-chain fatty acids, was associated with lower incidence of T2D. The specific fatty acid pattern may be influenced by metabolic, genetic, and dietary factors.
Collapse
Affiliation(s)
- Fumiaki Imamura
- Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Stephen J. Sharp
- Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Albert Koulman
- National Institute for Health Research Biomedical Research Centres Core Nutritional Biomarker Laboratory, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
- National Institute for Health Research Biomedical Research Centres Core Metabolomics and Lipidomics Laboratory, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
- Medical Research Council Epidemiology Unit Elsie Widdowson Laboratory, Cambridge, United Kingdom
| | - Matthias B. Schulze
- Department of Molecular Epidemiology, German Institute of Human Nutrition, Potsdam, Germany
| | - Janine Kröger
- Department of Molecular Epidemiology, German Institute of Human Nutrition, Potsdam, Germany
| | - Julian L. Griffin
- Medical Research Council Epidemiology Unit Elsie Widdowson Laboratory, Cambridge, United Kingdom
- Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
| | - José M. Huerta
- Department of Epidemiology, Consejería de Sanidad y Política Social, CIBER de Epidemiología y Salud Pública, Murcia, Spain
- CIBER Epidemiología y Salud Pública, Madrid, Spain
| | - Marcela Guevara
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Navarre Public Health Institute, Pamplona, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Ivonne Sluijs
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Antonio Agudo
- Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Barcelona, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Navarre Public Health Institute, Pamplona, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Beverley Balkau
- Center for Research in Epidemiology and Population Health, Inserm U1018, Paris-Sud University, University Versailles Saint-Quentin-en-Yvelines, Paris Saclay University, Villejuif, France
| | - Heiner Boeing
- Department of Molecular Epidemiology, German Institute of Human Nutrition, Potsdam, Germany
| | | | - Christina C. Dahm
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Courtney Dow
- Center for Research in Epidemiology and Population Health, Inserm U1018, Paris-Sud University, University Versailles Saint-Quentin-en-Yvelines, Paris Saclay University, Villejuif, France
- Gustave Roussy Institute, Villejuif, France
| | - Guy Fagherazzi
- Center for Research in Epidemiology and Population Health, Inserm U1018, Paris-Sud University, University Versailles Saint-Quentin-en-Yvelines, Paris Saclay University, Villejuif, France
- Gustave Roussy Institute, Villejuif, France
| | - Edith J. M. Feskens
- Department of Agrotechnology and Food Sciences, Wageningen University, Wageningen, Netherlands
| | - Paul W. Franks
- Family Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
- Department of Clinical Sciences, Lund University, Skane University Hospital, Malmo, Sweden
| | - Diana Gavrila
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain
- Murcia BioHealth Research Institute–Hospital Virgen de la Arrixaca, Murcia, Spain
| | - Marc Gunter
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Timothy J. Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Kay-Tee Khaw
- Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Olle Melander
- Department of Clinical Sciences, Lund University, Skane University Hospital, Malmo, Sweden
| | - Elena Molina-Portillo
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
| | - Peter M. Nilsson
- Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
| | - Anja Olsen
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Kim Overvad
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
- Department of Cardiology, Aalborg University Hospital, Aarhus, Denmark
| | - Domenico Palli
- Cancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute, Florence, Italy
| | - Salvatore Panico
- Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Federico II University, Naples, Italy
| | - Olov Rolandsson
- Family Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
| | - Sabina Sieri
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology, Città della Salute e della Scienza Hospital–University of Turin and Center for Cancer Prevention, Torino, Italy
| | - Nadia Slimani
- International Agency for Research on Cancer, Lyon, France
| | | | | | - Rosario Tumino
- Affiliation Cancer Registry, Department of Prevention, Azienda Sanitaria Provinciale di Ragusa, Ragusa, Italy
| | - Yvonne T. van der Schouw
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Claudia Langenberg
- Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Elio Riboli
- School of Public Health, Imperial College London, London, United Kingdom
| | - Nita G. Forouhi
- Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Nick J. Wareham
- Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|